- Robert Straus Behavioral Science Laboratory
- 845 Angliana Avenue
- Lexington, KY 40508
Dr. Lofwall continues to spend the majority of her time conducting clinical research. This past 2016 she completed a pivotal study as P.I. for a 36-site Phase III randomized double-dummy double-blind outpatient clinical trial evaluating the efficacy and safety of subcutaneous buprenorphine weekly and monthly injections among adults with moderate – severe opioid use disorder. Results will be presented to FDA for approval in 2017. In early 2016, she served as a speaker for the sponsor of a different study evaluating Probuphine® (she was a site-PI) at the FDA Advisory Committee Meeting; Probuphine® was subsequently approved in May 2016. She also is the co-investigator and medically responsible physician on several other NIDA-funded outpatient and inpatient studies (Phase II and Phase III trials) with (PI’s: Walsh, Knudsen, Havens). She has initiated new research collaborations with the College of Nursing (Kristen Ashford, APRN) and the Division of Hospital Medicine (Laura Fanucchi, MD). Dr. Lofwall published seven peer-reviewed manuscripts and has one in press (1 first author, 1 senior author) this year in highly respected journals (e.g., NEJM and JAMA). She presented her research at international and national meetings (e.g., American Society and International Society of Addiction Medicine [ASAM & ISAM]), was also asked to teach in England at the Improving Outcomes in the Treatment of Opioid Dependence Conference and to serve on SAMHSA’s expert panel for the writing of a TIP toolkit on opioid use disorder treatment as was directed by Congress in the new CARA legislation. She worked with Dr. Walsh (as co-PI) on a PCORI grant application (under review), with Dr. Fanucchi and Walsh on a UK MVP application (awarded this November), and with Dr. Ashford on two grants [a NIDA grant application and a MVP application (under review)]. With regards to public and professional society service, Dr. Lofwall is the co-course director for the annual 3.5 day addiction psychiatry review course for AAAP, provided several buprenorphine trainings in KY, and served as a grant reviewer for NIDA and SAMHSA. She serves on the ASAM scientific program committee and was recently asked to serve on the ASAM board. Dr. Lofwall continues to serve as an elected member to the Governor’s Kentucky All Schedule Prescription Electronic Reporting Advisory Council (second term). She has continued to provide state-of-the-art addiction treatment education to physicians (e.g., she in a mentor through SAMHSA-funded Physician Clinical Support System for Medication Assisted Treatment [PCSS-MAT]) and continues to serve as a volunteer addiction psychiatry consultant to Dr. Critchfield (high risk MFM OB/GYN physician directing the UK Pathway clinic that provides buprenorphine treatment to opioid-addicted pregnant women). She has also helped Dr. Fanucchi start her buprenorphine treatment clinic for HIV + patients within the outpatient infectious disease department at UK and assisted UK CE Central in developing a CME activity for physicians aimed at appropriate opioid prescribing and addiction treatment in response to an award from the CDC (PI: Terry Bunn, Ph.D.) Dr. Lofwall continues to serve the educational mission of UK as illustrated by several of the activities above. As well, she is on the dissertation committee for four Ph. D. students, mentors two junior faculty, teaches UK psychiatry residents, medical students (MD-813), physician assistant students (PAS-655), dental pain fellows and provides weekly individual psychiatry resident supervision to two residents. She also is working on a team led by Dr. Fanucchi to develop a clinical proposal for a continuum of addiction treatment services throughout the UK Enterprise and was recently asked to assist with development of hospital protocols for opioid withdrawal and initiation of maintenance treatment and treatment of pain among persons maintained on buprenorphine.